Earnings Feed
Start Free
TEVA PHARMACEUTICAL INDUSTRIES LTD·4

Mar 6, 4:09 PM ET

Hughes Eric A 4

Research Summary

AI-generated summary

Updated

TEVA (TEVA) Exec VP Eric A. Hughes Sells 11,277 Shares

What Happened

  • Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer of TEVA, reported multiple transactions on March 4, 2026. He sold 11,277 ordinary shares in an open-market transaction for total proceeds of $366,102 (weighted average price $32.46). The sale was carried out under a Rule 10b5‑1 trading plan.
  • The filing also reports conversion/exercise entries of 23,251 derivative units and the grant/award of 50,643 restricted share units (RSUs). One derivative disposal entry shows $0 proceeds, reflecting the non‑cash settlement/conversion of awards rather than a market sale.

Key Details

  • Transaction date: March 4, 2026.
  • Open-market sale: 11,277 shares at a weighted average price of $32.46; total reported proceeds $366,102. Price range for the sales: $32.095–$33.30 (per filing).
  • Derivative activity: 23,251 shares reported as exercised/converted (M) and 23,251 reported as disposed at $0 — this reflects settlement/conversion of derivative awards.
  • Grant: 50,643 restricted share units (A) reported on March 4, 2026.
  • Purpose of sale: Footnote states 11,277 shares were sold to cover tax withholding obligations related to RSU vesting.
  • Plan and rules: Sale executed pursuant to a Rule 10b5‑1 trading plan adopted Nov 10, 2025.
  • Vesting notes: Prior RSU grant (March 4, 2024) had 23,251 vestings on March 4, 2025 and March 4, 2026, with remaining vesting through 2028; the new RSU grant (Mar 4, 2026) vests in installments 2027–2030 (see footnotes).
  • Shares owned after transaction: Not specified in the provided excerpt.
  • Filing timeliness: No late filing flag noted in the provided information.

Context

  • This filing combines RSU vesting/settlement and a routine tax‑withholding sale. The derivative/award entries indicate conversion or settlement of restricted share units rather than an exercised option followed by a market sale for profit taking.
  • Sales to cover tax withholding are common when equity awards vest and do not necessarily signal a change in insider sentiment. The 10b5‑1 plan indicates the sale was prearranged.